Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The safety of autologous adipose derived SVF combined with the ACAM2000 (Vaccinia) vaccine in patients with advanced solid tumors

Next Previous
Search
Trial Profile

The safety of autologous adipose derived SVF combined with the ACAM2000 (Vaccinia) vaccine in patients with advanced solid tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SI 001 (Primary) ; SI 001 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Calidi Biotherapeutics

    • Most Recent Events

    • 22 Jun 2020 According to a Calidi Biotherapeutics media release, data will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting II, which will be held in virtual format June 22 through June 24, 2020, due to COVID-19 concerns.
    • 06 Nov 2018 According to a Calidi Biotherapeutics media release, data from this trial ( safety findings and post-treatment observations of oncolytic vaccinia virus combined with adipose stromal vascular fraction (SVF) cells in autologous settings) will be presented at the Society for Immunotherapy of Cancer (SITC) upcoming 33rd Annual Meeting (7-11 Nov 2018, Washington, D.C.).
    • 31 Oct 2018 Results of this trial published online on Calidi Biotherapeutics website.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top